Share on Facebook Share on Twitter Share on Google Plus Share on Pinterest Share on Linkedin
by Taylor Howard on Tuesday February 2, 2021
Using Breakthrough CGRP Inhibitors To Prevent Migraines

Tampa General Hospital is home to one of the leading headache clinics in the region, offering relief to patients with refractory headaches and severe migraines. Using cutting edge therapies and new treatment options, such as nerve blocks, Botox injections, and new classes of CGRP (calcitonin gene-related peptide) inhibitor medicines, neurologists at Tampa General are at the forefront of this specialty.

Neurologists at Tampa General are participating in studies evaluating CGRP antagonists that could unlock migraine prevention. The purpose of the studies are to determine how study participants react to the leading CGRP inhibitor medicines available today.

CGRP is a peptide that dilates the cerebral and dural blood vessels and is found at increased levels during a migraine or cluster headache. CGRP antagonists are monoclonal antibodies that interrupt one of the pain signaling pathways in migraine. Studies have shown that one-third of patients being treated with CGRP antagonists see a 75% or higher improvement in headaches and a smaller subset of patients experienced almost total improvement.

CGRPs also regulate blood pressure, help with wound healing and contribute to homeostasis during ischemic events. Blocking them in certain patients may prevent cardiovascular risks. Neurologists at Tampa General’s headache clinic work with cardiologists in the heart failure clinic to ensure that candidates for CGRP inhibitors are pre-screened prior to receiving treatment.